What question did this study set out to answer?

To synthesize evidence on the association between the APOE ε3/ε4 genotype and coronary artery disease, focusing on lipid and non-lipid pathways, conventional risk interactions, and personalized prevention.

September 18, 2026Frontiers in Cardiovascular MedicineOpen Access

Apolipoprotein E ε3/ε4 and coronary artery disease: lipid and non-lipid mechanisms in personalized prevention — narrative review

View Full Paper

Ask AI

Bookmark

Authors

RDR Diaconu VPVlad Pădureanu RRRăzvan Ilie Radu

Discussion

Member takes

Overview

Narrative review reveals increased coronary artery disease risk linked to the APOE ε3/ε4 genotype, highlighting modest effects driven by lipid and non-lipid mechanisms.

Key Points

To synthesize evidence on the association between the APOE ε3/ε4 genotype and coronary artery disease, focusing on lipid and non-lipid pathways, conventional risk interactions, and personalized prevention.
Narrative review searching PubMed, Embase, Scopus, and Web of Science up to August 2026 using terms related to APOE genotypes, coronary artery disease, lipid metabolism, and atherosclerosis.
Included English-language original articles, reviews, and meta-analyses classified by genotype contrast and level of evidence across human observational, interventional, and experimental models.
Carrying the APOE ε3/ε4 genotype is linked to higher LDL cholesterol, apolipoprotein B, and remnant-lipoprotein concentrations, alongside impaired clearance of triglyceride-rich particles.
Beyond lipids, ApoE modulates inflammation, macrophage activity, oxidative stress, and endothelial function, though non-lipid pathways derive primarily from preclinical models.
Adjusted estimates referencing ε3/ε3 indicate a modest association with CAD, conferring odds ratios of approximately 1.5 for unselected CAD and 1.5 to 2.2 for premature coronary phenotypes.

Cite This Study

Diaconu et al. (2026) studied this question.

synapsesocial.com/papers/6ab1e1accb0350d79aefc3fb https://doi.org/10.3389/fcvm.2026.1885898

View Full Paper

Ask AI

Bookmark

September 18, 2026Frontiers in Cardiovascular MedicineOpen Access

Apolipoprotein E ε3/ε4 and coronary artery disease: lipid and non-lipid mechanisms in personalized prevention — narrative review

View Full Paper

Ask AI

Bookmark

Authors

RDR Diaconu VPVlad Pădureanu RRRăzvan Ilie Radu

Discussion

Member takes

Overview

Narrative review reveals increased coronary artery disease risk linked to the APOE ε3/ε4 genotype, highlighting modest effects driven by lipid and non-lipid mechanisms.

Key Points

To synthesize evidence on the association between the APOE ε3/ε4 genotype and coronary artery disease, focusing on lipid and non-lipid pathways, conventional risk interactions, and personalized prevention.
Narrative review searching PubMed, Embase, Scopus, and Web of Science up to August 2026 using terms related to APOE genotypes, coronary artery disease, lipid metabolism, and atherosclerosis.
Included English-language original articles, reviews, and meta-analyses classified by genotype contrast and level of evidence across human observational, interventional, and experimental models.
Carrying the APOE ε3/ε4 genotype is linked to higher LDL cholesterol, apolipoprotein B, and remnant-lipoprotein concentrations, alongside impaired clearance of triglyceride-rich particles.
Beyond lipids, ApoE modulates inflammation, macrophage activity, oxidative stress, and endothelial function, though non-lipid pathways derive primarily from preclinical models.
Adjusted estimates referencing ε3/ε3 indicate a modest association with CAD, conferring odds ratios of approximately 1.5 for unselected CAD and 1.5 to 2.2 for premature coronary phenotypes.

Cite This Study

Diaconu et al. (2026) studied this question.

synapsesocial.com/papers/6ab1e1accb0350d79aefc3fb https://doi.org/10.3389/fcvm.2026.1885898

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark